Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00496 |
| Species: | Homo sapiens |
| Position : | chr15:45700000-45701000 |
| Year: | 2023 |
| Title: | Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | pancreatic ductal adenocarcinoma |
| PMID: | 37370109 |
| MONDO: | MONDO:0005147 |
| Tissue: | Pancreas |
| Tissue Ontology ID: | UBERON:0001264 |
| Cell Source: | PANC-1-IN |
| CVCL ID: | |
| Cell Type: | pancreatic ductal adenocarcinoma cell |
| Cell Ontology ID: | CL:0000066 |
| Experiment Type: | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| High Throughput Method: | Hi-C, ChIP-seq |
| Low Throughput Method: | CRISPRi (dCas9-KRAB), ChIP-RT-qPCR, 3C-RT-qPCR, RT-RT-qPCR, Western blot |
| Target gene : | GATM |
| TF name : |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|